Tempus AI (NASDAQ:TEM) Shares Up 13.1% – Time to Buy?

Tempus AI, Inc. (NASDAQ:TEM)’s share price traded up 13.1% during trading on Monday . The company traded as high as $57.69 and last traded at $58.10. 6,508,913 shares were traded during trading, a decline of 52% from the average session volume of 13,653,986 shares. The stock had previously closed at $51.35.

Analysts Set New Price Targets

A number of analysts have issued reports on TEM shares. Needham & Company LLC lifted their price objective on Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. TD Cowen restated a “buy” rating and issued a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Wolfe Research downgraded shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Bank of America lifted their price objective on shares of Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. Finally, William Blair restated a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $61.18.

Tempus AI Stock Performance

The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The stock’s 50-day moving average is $57.42 and its two-hundred day moving average is $51.46.

Insider Activity

In other Tempus AI news, Director David R. Epstein sold 990 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $46.83, for a total value of $46,361.70. Following the completion of the sale, the director now directly owns 26,284 shares of the company’s stock, valued at $1,230,879.72. The trade was a 3.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jennifer A. Doudna sold 1,320 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $90.00, for a total transaction of $118,800.00. Following the completion of the transaction, the director now owns 36,011 shares in the company, valued at $3,240,990. This represents a 3.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,598,969 shares of company stock valued at $317,194,162.

Institutional Trading of Tempus AI

A number of large investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in Tempus AI by 13.2% during the 4th quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock valued at $80,000 after purchasing an additional 278 shares in the last quarter. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI in the 3rd quarter valued at $30,000. Geode Capital Management LLC raised its position in shares of Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after acquiring an additional 539 shares in the last quarter. Operose Advisors LLC bought a new position in shares of Tempus AI in the 4th quarter worth $25,000. Finally, Prestige Wealth Management Group LLC lifted its stake in shares of Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after purchasing an additional 965 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.